1-aminocyclobutanecarboxylic acid: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 89643 |
| CHEMBL ID | 131244 |
| CHEBI ID | 190867 |
| SCHEMBL ID | 61734 |
| MeSH ID | M0067412 |
| Synonym |
|---|
| AC-5714 |
| bdbm50038160 |
| DIVK1C_006749 |
| nsc 403363 |
| brn 2802253 |
| cb 1700 |
| 1-aminocyclobutanecarboxlic acid |
| NCGC00024518-01 |
| tocris-0258 |
| nsc-403362 |
| BSPBIO_002326 |
| cyclobutanecarboxylic acid, 1-amino- |
| 1-aminocyclobutanecarboxylic acid |
| nsc-403363 |
| 22264-50-2 |
| nsc403363 |
| 1-amino-1-cyclobutanecarboxylic acid, 97% |
| 1Y1Z |
| 1-aminocyclobutane-1-carboxylic acid |
| KBIO3_001546 |
| KBIO1_001693 |
| KBIOGR_001312 |
| SPECPLUS_000653 |
| SPECTRUM2_001476 |
| SPBIO_001431 |
| SPECTRUM4_001046 |
| SPECTRUM3_000743 |
| SPECTRUM5_001835 |
| NCGC00024518-02 |
| STK330996 |
| 1-amino-cyclobutanecarboxylic acid |
| CHEMBL131244 , |
| FT-0655686 |
| FT-0657756 |
| CHEBI:190867 |
| 1-aminocyclobutane carboxylic acid |
| A4782 |
| BBL001782 |
| 1-aminocyclobutanecarboxylicacid |
| 3-14-00-00843 (beilstein handbook reference) |
| unii-1k1pgc7j6z |
| 1k1pgc7j6z , |
| A816068 |
| 22264-16-0 |
| CCG-39205 |
| AKOS005172352 |
| FT-0638207 |
| 1-amino-1-cyclobutanecarboxylic acid |
| AM20070607 |
| PB32216 |
| AB00053379-03 |
| SCHEMBL61734 |
| acbc |
| 1-amino-1-cyclobutane carboxylic acid |
| J-504194 |
| TS-01591 |
| HB0100 |
| DTXSID60176811 |
| mfcd00661068 |
| SR-01000597721-1 |
| sr-01000597721 |
| CS-D0209 |
| HY-30006 |
| 117259-24-2 |
| Q1147632 |
| tert-butoxycarbonylamino-(4-tert-butoxycarbonylamino-phenyl)-aceticacid |
| 1-amino-1-cyclobutanecarboxylicacid |
| SB10822 |
| NCGC00024518-03 |
| 1-amino-1-cyclobutane carboxylic acid hydrochloride |
| EN300-93167 |
| PD071292 |
| SY002606 |
| Class | Description |
|---|---|
| L-alpha-amino acid | Any alpha-amino acid having L-configuration at the alpha-carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 79.4328 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.5893 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Glutamate [NMDA] receptor subunit zeta 1 | Rattus norvegicus (Norway rat) | Ki | 831.0000 | 4.8000 | 5,378.6000 | 15,300.0000 | AID977610 |
| Chain A, Glutamate [NMDA] receptor subunit zeta 1 | Rattus norvegicus (Norway rat) | Ki | 831.0000 | 4.8000 | 5,378.6000 | 15,300.0000 | AID977610 |
| Chain A, Glutamate [NMDA] receptor subunit zeta 1 | Rattus norvegicus (Norway rat) | Ki | 831.0000 | 4.8000 | 5,378.6000 | 15,300.0000 | AID977610 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 19.0000 | 0.0007 | 1.6003 | 10.0000 | AID145260 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 19.0000 | 0.0007 | 1.6306 | 10.0000 | AID145260 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 19.0000 | 0.0006 | 1.5257 | 10.0000 | AID145260 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.7500 | 0.0007 | 1.7472 | 10.0000 | AID144708; AID145260 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 (µMol) | 19.0000 | 0.0007 | 1.7411 | 10.0000 | AID145260 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 19.0000 | 0.0007 | 1.7411 | 10.0000 | AID145260 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 19.0000 | 0.0007 | 1.7411 | 10.0000 | AID145260 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2005 | Neuron, Jul-07, Volume: 47, Issue:1 | Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2005 | Neuron, Jul-07, Volume: 47, Issue:1 | Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID144708 | Compound was evaluated for in vitro inhibition of oocytes at NMDA receptor. | 1994 | Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24 | The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. |
| AID430782 | Displacement of [3H]glycine from strychnine-insensitive glycine recognition site of NMDA receptor in rat brain cortex membrane | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex. |
| AID430786 | Partial agonist activity at glycine site of NMDA receptor in rat brain cortex membrane assessed as potentiation of [3H]Mk-801 binding by liquid scintillation counting relative to glycine in presence of antagonist 5,7-dichlorokynurenic acid | 2009 | Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16 | Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID145260 | In vitro inhibition of [3H]glycine at NMDA receptor | 1994 | Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24 | The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (20.00) | 18.7374 |
| 1990's | 11 (44.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 4 (16.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor. Neuropharmacology, Volume: 29, Issue: 3 | 1990 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |